San Francisco Sentry Investment Group’s Sarepta Therapeutics SRPT Stock Holding History

San Francisco Sentry Investment Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$25K	Sell	324 -3	-0.9%	-$227	0.01%	455
2021 Q1	$24K	Buy	327 +113	+53%	+$10.4K	0.01%	469
2020 Q4	$37K	Sell	214 -1	-0.5%	-$148	0.02%	393
2020 Q3	$30K	Sell	215 -5	-2%	-$760	0.02%	390
2020 Q2	$35K	Sell	220 -47	-18%	-$6.4K	0.02%	372
2020 Q1	$26K	Hold	267	–	–	0.02%	357
2019 Q4	$34K	Buy	+267	New	+$26.9K	0.02%	424
2018 Q4	–	Sell	-6	Closed	-$1K	–	1062
2018 Q3	$1K	Buy	+6	New	+$820	﹤0.01%	872

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

San Francisco Sentry Investment Group's SRPT Position: Q2 2021 in Review

San Francisco Sentry Investment Group reduced its Sarepta Therapeutics (SRPT) stake by 0.92% in Q2 2021, selling an estimated $227 and leaving 324 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #455.

San Francisco Sentry Investment Group first reported a position in SRPT in Q3 2018 and has held it in 8 quarters since. The position peaked at $37K in Q4 2020. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

San Francisco Sentry Investment Group held 324 shares of Sarepta Therapeutics worth $25K as of Q2 2021.
San Francisco Sentry Investment Group sold 3 Sarepta Therapeutics shares in Q2 2021, an estimated $227.
Sarepta Therapeutics made up 0.01% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #455 holding.
San Francisco Sentry Investment Group first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 8 quarters since.
San Francisco Sentry Investment Group's Sarepta Therapeutics position peaked at $37K in Q4 2020.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.